Objective Gynecological brain metastases (BM) are rare and usually develop as part of widespread disseminated disease. Despite treatment, the majority of these patients do not survive>1 year due to advanced extracranial disease. The use of Gamma Knife Radiosurgery (GKRS) for gynecological BM is not well known. The goal of this study is to evaluate the efficacy of GKRS for gynecological BM. Methods We performed a retrospective study of patients with gynecological BM who underwent GKRS between 2002 and 2015. A total of 41 patients were included. Outcome measures were local tumor control (LC), development of new BM and/ or leptomeningeal disease, overall intracranial progression free survival (PFS) and survival. Results LC was 100%, 92%, 80%, 75% and 67% at 3, 6, 9, 12 and 15 months, respectively. PFS was 90%, 61%, 41%, 23% and 13% at 3, 6, 9, 12 and 15 months, respectively. During follow-up (FU), 18 (44%) patients had intracranial progression. Distant BM occurred in 29% of the patients. Local recurrence and distant recurrence occurred after a mean FU time of 15.5 (2.6–71.9) and 11.4 (2–40) months, respectively. Thirty-one (76%) patients died due to extracranial tumor progression and only 2 (5%) patients died due to progressive intracranial disease. The overall mean survival from time of GKRS was 19 months (1–109). The 6-month, 1-year, and 2-year survival rate from the time of GKRS were 71%, 46%, and 22%, respectively. Conclusion GKRS is a good treatment option for controlling gynecological BM. As most patients die due to extracranial tumor progression, their survival might improve with better systemic treatment options in addition to GKRS.

Additional Metadata
Keywords Gynecological tumors · Gynecological brain metastases · Gamma knife radiosurgery
Persistent URL dx.doi.org/10.1007/s11060-019-03094-2, hdl.handle.net/1765/116148
Journal Journal of Neuro-Oncology
Sadik, Z.H.A., Beerepoot, L.V, & Hanssens, PEJ. (2019). Efficacy of gamma knife radiosurgery in brain metastases of primary gynecological tumors. Journal of Neuro-Oncology, 142(2), 283–290. doi:10.1007/s11060-019-03094-2